Literature DB >> 25064356

Orphan nuclear receptor Nur77 promotes colorectal cancer invasion and metastasis by regulating MMP-9 and E-cadherin.

Jing-Ru Wang1, Wen-Juan Gan2, Xiu-Ming Li1, Yuan-Yuan Zhao1, Ying Li3, Xing-Xing Lu1, Jian-Ming Li4, Hua Wu5.   

Abstract

Nur77, an orphan member of the nuclear receptor superfamily, has been implicated in tumorigenesis. However, its contributions to colorectal cancer (CRC) invasion and metastasis are largely under characterized. Here, we present the first evidence that the invasion and metastasis of CRC is regulated by Nur77. High expression of Nur77 was observed in clinical CRC tissues, and this elevated expression was significantly associated with advanced tumor, lymph nodes, distant metastasis stage (P = 0.003), lymph node metastasis (P = 0.001) and poor survival (P = 0.03). Overexpression of Nur77 in CRC cells enhanced cell invasion in vitro, whereas knockdown of Nur77 diminished cell invasion and metastasis both in vitro and in vivo. In studying the possible mechanism by which overexpression of Nur77 contributes to CRC invasion and metastasis, we observed that the nuclear protein Nur77 promoted the expression of matrix metalloproteinase (MMP)-9, a novel downstream target of Nur77, and subsequently decreased the expression of E-cadherin. Examination of clinical samples further showed that Nur77 expression is positively correlated with MMP-9, whereas negatively correlated with E-cadherin. Interestingly, Nur77-mediated CRC invasion via MMP-9 and E-cadherin could be mimicked by some metastasis-inducible factors including hypoxia and prostaglandin E2. Collectively, our study demonstrated that Nur77 could promote the invasion and metastasis of CRC cells through regulation of MMP-9/E-cadherin signaling. These observations provide a possible new strategy for potentially treating or preventing the metastasis of CRC through targeting of Nur77.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25064356     DOI: 10.1093/carcin/bgu157

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  35 in total

Review 1.  Structure-dependent activation of gene expression by bis-indole and quinoline-derived activators of nuclear receptor 4A2.

Authors:  Xi Li; Ronald B Tjalkens; Rupesh Shrestha; Stephen Safe
Journal:  Chem Biol Drug Des       Date:  2019-07-21       Impact factor: 2.817

2.  Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.

Authors:  Erik Hedrick; Kumaravel Mohankumar; Alexandra Lacey; Stephen Safe
Journal:  Mol Cancer Res       Date:  2019-08-28       Impact factor: 5.852

3.  Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.

Authors:  Erik Hedrick; Xi Li; Yating Cheng; Alexandra Lacey; Kumaravel Mohankumar; Mahsa Zarei; Stephen Safe
Journal:  Breast Cancer Res Treat       Date:  2019-05-22       Impact factor: 4.872

4.  Bis-indole derived nuclear receptor 4A1 (NR4A1) antagonists inhibit TGFβ-induced invasion of embryonal rhabdomyosarcoma cells.

Authors:  Rupesh Shrestha; Kumaravel Mohankumar; Stephen Safe
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 6.166

5.  Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1.

Authors:  Melanie D Mumau; Ashley N Vanderbeck; Elizabeth D Lynch; Sophia B Golec; Stephen G Emerson; Jennifer A Punt
Journal:  J Immunol       Date:  2017-12-27       Impact factor: 5.422

6.  PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.

Authors:  Alexandra Lacey; Aline Rodrigues-Hoffman; Stephen Safe
Journal:  Cancer Res       Date:  2016-11-18       Impact factor: 12.701

7.  The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists.

Authors:  Erik Hedrick; Syng-Ook Lee; Stephen Safe
Journal:  Mol Carcinog       Date:  2017-05-09       Impact factor: 4.784

8.  Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.

Authors:  Kumaravel Mohankumar; Xi Li; Subhashree Sridharan; Keshav Karki; Stephen Safe
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

9.  Nuclear receptor 4A (NR4A) family - orphans no more.

Authors:  Stephen Safe; Un-Ho Jin; Benjamin Morpurgo; Ala Abudayyeh; Mandip Singh; Ronald B Tjalkens
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-23       Impact factor: 4.292

10.  Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis.

Authors:  Kumaravel Mohankumar; Xi Li; Nuri Sung; Yeon Jean Cho; Sang Jun Han; Stephen Safe
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.